|
Hutchmed (China) Limited is a commercial-stage biopharmaceutical company engaged in the research, development, manufacture, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company operates a fully integrated platform that spans discovery, development, manufacturing, and commercialization. Its business segments include the provision of professional scientific and technical support services, as well as sales, distribution, and marketing services to pharmaceutical manufacturers. Hutchmed manufactures and distributes healthcare products, including prescription drugs and consumer health products, in China. The company maintains GMP-standard manufacturing facilities in Suzhou and Shanghai, China, and has qualified drug product sites in Switzerland to support global supply. It serves markets in China, the United States, the European Union, and Japan. Notable products include FRUZAQLA (fruquintinib), ATLED (fanregratinib), and ORPATHYS (savolitinib). The company has established a licensing agreement with GSK for the KRAS-EGFR antibody-targeted therapy conjugate HMPL-A830. Hutchmed has operated in the pharmaceutical sector for over two decades. Summarised from the company's own disclosures, fiscal year ended Apr 2026 |
Industry Biotechnology | Homepage hutch-med.com |
| Sector Healthcare | IR page hutch-med.com | |
|
Tags
oncology, immunology, targeted therapies, immunotherapies, cancer treatment, drug discovery, clinical trials, pharmaceutical manufacturing, biopharmaceuticals, precision medicine, FRUZAQLA, fruquintinib, ATLED, fanregratinib, ORPATHYS, savolitinib, TAGRISSO, HMPL-A830, SANOVO, SAFFRON, SACHI, FRESCO-2, ESLIM-01, Sovleplenib
|
Press page hutch-med.com/news |
Metrics
| Valuation | |
|---|---|
| Market cap | HK$ 18.73B |
| Market cap (USD) | $ 2.387B |
| P/E | 5.18 |
| PEG | — |
| P/BV | 1.91 |
| P/S | 4.35 |
| P/OCF | -36.92 |
| P/FCF | — |
| Dividend yield | — |
| Turnover / mcap | 0.41% |
| Returns | |
|---|---|
| ROE | 371.5% |
| ROI | 483.3% |
| ROIC | 483.3% |
| Profit margin | 83.4% |
| Growth | |
|---|---|
| Revenue growing | No |
| Profits growing | Yes |
| Revenue up 3y | No |
| Revenue up 5y | No |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | No |
| Buying back stock | No |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | 12.5% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 548.512M | 630.201M | 837.999M | 426.409M | 356.128M | 227.976M | 204.89M | 214.109M | 241.203M | 216.08M | 178.203M |
| Net profit | 456.909M | 37.729M | 100.78M | -360.835M | -194.648M | -125.73M | -106.024M | -74.805M | -26.737M | 11.698M | 7.993M |
| Free cash flow | -78.805M | -17.436M | 186.646M | -305.263M | -220.624M | -70.015M | -89.477M | -39.211M | -13.962M | -13.896M | -12.709M |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (USD) | 40.8M | 38.4M | 40.2M | 41.4M | 46.6M | 83.6M | 98M | 117M | 156M | 127M |
| ↳ YoY growth | +22.4% | -5.9% | +4.6% | +3.1% | +12.6% | +79.2% | +17.2% | +19.3% | +33.1% | -18.5% |
| ↳ 5y CAGR | +6.9% | +15.4% | +20.6% | +23.8% | +30.3% | +22.1% | ||||
| Borrowings, current (USD) | 20M | 30M | — | — | — | 26.9M | — | 62.3M | 46.7M | 49.9M |
| Borrowings, non-current (USD) | 26.8M | — | 26.7M | 26.8M | 26.9M | — | 18.1M | 48.2M | 59.4M | 68.2M |
| Lease liabilities (USD) | — | — | 6.36M | 6.27M | 8.85M | 12.1M | 8.9M | 6.79M | 7.01M | 4.73M |
| Cash and deposits (USD) | 79.4M | 85.3M | 86M | 121M | 236M | 378M | 313M | 284M | 154M | 71.3M |
| Intangible assets (USD) | 469,000 | 430,000 | 347,000 | 275,000 | 227,000 | 163,000 | 85,000 | 21,000 | — | 8.94M |
| Right-of-use assets (USD) | — | — | 5.7M | 5.52M | 8.02M | 11.9M | 8.72M | 4.67M | 4.5M | 3.03M |
| Net debt (borrowings + leases - cash) (USD) | -52.6M | -55.3M | -59.3M | -88.1M | -200M | -339M | -286M | -166M | -40.8M | 51.5M |
| Cash flow detail | ||||||||||
| Operating cash flow (USD) | -9.57M | -8.94M | -32.8M | -80.9M | -62.1M | -204M | -269M | 219M | 497,000 | -64.7M |
| Purchases of property, plant and equipment (USD) | -4.33M | -5.02M | -6.36M | -8.57M | -7.95M | -16.4M | -36.7M | -32.6M | -17.9M | -14.1M |
| Purchases of intangible assets (USD) | — | — | — | — | — | — | — | — | — | -10M |
| Change in receivables (cash effect) (USD) | -7.26M | 2.16M | -1.56M | -1.21M | -5.32M | -35.6M | -14.5M | -21.3M | -38.5M | 28.9M |
| Change in inventories (cash effect) (USD) | -3.43M | 1.05M | -557,000 | -4.22M | -3.62M | -16M | -21.2M | 4.14M | -772,000 | 9.54M |
| Change in payables (cash effect) (USD) | 9.82M | -11.2M | 1.26M | -1.66M | 7.65M | 9.57M | 29.9M | -32.5M | 6.19M | 3.01M |
| Share buybacks (cash effect) (USD) | -604,000 | -1.37M | -5.45M | -346,000 | -12.9M | -27.3M | -48.1M | -9.07M | -36.1M | — |
| Interest paid (cash effect) (USD) | -1.57M | -763,000 | -979,000 | -917,000 | -815,000 | -425,000 | -150,000 | -421,000 | -2.51M | -2.52M |
| Income taxes paid (cash effect) (USD) | 2.66M | -3.84M | -3.75M | -3.25M | -5.94M | -5.01M | -18.9M | -3.73M | -3.59M | -62.4M |
| Operating cash flow before change in receivables (USD) | -2.31M | -11.1M | -31.3M | -79.7M | -56.8M | -169M | -254M | 241M | 39M | -93.5M |
| Free cash flow (OCF - PPE - intangibles) (USD) | -13.9M | -14M | -39.2M | -89.5M | -70M | -221M | -305M | 187M | -17.4M | -88.8M |
| Income detail | ||||||||||
| Research and development expense (USD) | 66.9M | 75.5M | 114M | 138M | 175M | 299M | 387M | 302M | 212M | 148M |
| ↳ 5y CAGR | +35.8% | +29.8% | +34.9% | +38.6% | +21.5% | +8.9% | -3.2% | |||
| Total comprehensive income (USD) | 3.84M | -12M | -77.9M | -108M | -106M | -164M | -369M | 94.5M | 34.4M | 460M |
| Comprehensive income to owners (USD) | 2.41M | -17M | -80.5M | -110M | -117M | -192M | -368M | 94.5M | 34.3M | 459M |
| Provision for credit losses (USD) | 29,000 | 242,000 | 21,000 | 16,000 | 95,000 | 16,000 | 150,000 | 141,000 | 70,000 | 3,000 |
| Credit cost ratio (credit losses / average receivables) (%) | 0.1% | 0.6% | 0.1% | 0.0% | 0.2% | 0.0% | 0.2% | 0.1% | 0.1% | 0.0% |
| Reported | Mar 12, 2018 | Mar 12, 2018 | Mar 3, 2020 | Mar 3, 2020 | Mar 4, 2021 | Mar 3, 2022 | Feb 28, 2023 | Feb 28, 2024 | Mar 19, 2025 | Mar 5, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpAnnouncements and reports published on HKEXnews, newest first, monthly and next-day returns, proxy forms and board-meeting notices included. The link opens the announcement on HKEXnews. Material events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR. Results, director/PDMR dealings and voting-rights totals announced to the FCA's National Storage Mechanism, newest first. The link opens the announcement on the NSM. Press releases from the company's own website, newest first.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Hutchmed (China) Limited
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
